HHS Proposes Sweeping Changes to AKS and Stark Law, Part 4: Modifications to Key Stark Law Terminology and a New Stark Law Exception

Mintz - Health Care Viewpoints
Contact

Mintz - Health Care Viewpoints

This post is the fourth installment of our blog series on significant, proposed changes to the Anti-Kickback Statute (AKS) and the Physician Self-Referral Law (commonly known as the Stark Law) recently announced by the Department of Health & Human Services (HHS).  The proposed rule issued by the Centers for Medicare & Medicaid Services (CMS) offers new and revised definitions on key Stark Law terms, some of which CMS has previously neglected to define or provide significant guidance.  In addition, CMS proposes a new Stark Law exception for limited remuneration to a physician, which offers health care entities more flexibility for unwritten, short-term compensation arrangements with physicians.

Commercially Reasonable

Even though several commonly used Stark Law exceptions require that the arrangement be commercially reasonable, CMS has never defined this key term and only briefly addressed the concept more than fifteen years ago in the Stark II Phase II rulemaking.

CMS is now proposing two alternative definitions for the term “commercially reasonable”:

  1. “The particular arrangement furthers a legitimate business purpose of the parties and is on similar terms and conditions as like arrangements.” 
  2. “The arrangement makes commercial sense and is entered into by a reasonable entity of similar type and size and a reasonable physician of similar scope and specialty.” (Note that this is the same language from the Stark II Phase II rulemaking.)

While a definition for this key term is a welcome update, commenters should consider at least two issues.  First, both definitions include numerous undefined terms, such as legitimate business purpose, commercial sense, and reasonable entity.  Second, the definition discussed in the Stark II Phase II rulemaking seems to offer less flexibility because it would require the parties to determine what constitutes a “reasonable entity of similar type and size” and a “reasonable physician of similar scope and specialty” whereas the first definition mentions only “similar terms and conditions as like arrangements.” Given that “commercially reasonable” is a key concept that applies to numerous exceptions, this proposed new definition is ripe for comments.

Perhaps more importantly, CMS also proposes regulatory language to clarify that an arrangement may be commercially reasonable even if it does not result in profit for one or more parties, which dispels the widespread misconception that a commercially reasonable arrangement must be profitable.  CMS recognizes that health care providers have a variety of business reasons for entering into arrangements with physicians.

Remuneration

CMS proposes a change to the definition of “remuneration” that should interest the laboratory industry.  The current definition excludes “the furnishing [by a laboratory] of items, devices or supplies (not including surgical items, devices or supplies) that are used solely for” specimen collection, transport, processing, or storage, or the ordering of laboratory tests or communication of results.  This exception allows laboratories to provide collection supplies to physicians as well as the technology necessary to allow physicians to submit orders and receive results electronically without violating the Stark Law. 

CMS proposes to delete the parenthetical related to surgical items, devices, or supplies, because it no longer believes that the mere fact that an item, device, or supply is routinely used as part of a surgical procedure means that it is not used solely for one of the permitted purposes.  In the proposed rule, CMS discusses two relevant CMS advisory opinions, 13-01 and 13-02, both of which involved arrangements where laboratories would provide at no charge to physicians disposable, single-use devices used to collect specimens.  Advisory Opinion 13-01 concerned liquid-based Pap smear specimen collection kits while Advisory Opinion 13-02 involved disposable biopsy brushes.  Even though the arrangements were similar, CMS arrived at different conclusions because it considered a biopsy brush to be a “surgical item, device, or supply.”  CMS now views the distinction between the two devices to be arbitrary and thus has proposed deleting the parenthetical.  However, CMS continues to believe this carve-out is limited to single-use items, devices, or supplies of low value.

CMS also seeks to add “in fact” before “solely” to clarify that an item, device, or supply could be used for another purpose, but that it is not remuneration if it is “in fact” used for one of the permitted purposes.  Lastly, CMS clarifies that an item, device, or supply with a primary function of preventing infection or contamination (such as latex gloves) is not excluded from the definition of remuneration under this carve-out.

Laboratories should carefully consider this proposal.  While it offers laboratories more flexibility in providing collection supplies to physicians, it could lead to increased costs if physicians ask for or expect laboratories to provide costly collection supplies they did not previously provide due to this regulation.

Designated Health Services

CMS proposes to revise the definition of “designated health services” (DHS) to clarify that a service provided by a hospital on an inpatient basis does not constitute a DHS if the furnishing of the service does not affect the amount of Medicare’s payment to the hospital under the Acute Hospital Inpatient Prospective Payment System (IPPS).  The rationale here is that physicians have no financial incentive to over-prescribe services that do not affect the rate of payment.

For example, the proposed rule describes a situation where an inpatient has been admitted to a hospital under an established diagnosis‐related group (DRG), and a specialist who was not responsible for the patient’s admission orders an X-ray.  Because the previously established DRG determines the rate of reimbursement under the IPPS, the X-ray generally would not result in the hospital receiving additional payment.  The X-ray thus would not be DHS under the revised definition, meaning that the specialist could have a financial relationship with the hospital that does not satisfy a Stark Law exception, and the hospital could nevertheless bill Medicare for the inpatient hospital services without violating the Stark Law.  This change would significantly reduce the scope of the Stark Law prohibitions.

Fair Market Value

An overarching principle running through most of the Stark Law exceptions is that the compensation must be consistent with fair market value (FMV).  The statute defines FMV to mean “the value in arms length transactions, consistent with the general market value, and, with respect to rentals or leases, the value of rental property for general commercial purposes (not taking into account its intended use) and, in the case of a lease of space, not adjusted to reflect the additional value the prospective lessee or lessor would attribute to the proximity or convenience to the lessor where the lessor is a potential source of patient referrals to the lessee,” and the regulations build upon the statutory definition. 

CMS proposes to replace the current regulatory definition with a general definition of FMV and more specific definitions applicable to rental of office space and rental of equipment.  Additionally, CMS proposes to remove from the FMV definition references to taking into account the volume or value of referrals, which is an independent requirement that CMS believes should not be part of the definition for FMV.  Overall, these changes just reorganize the definition for clarity but offer no significant substantive differences.

Isolated Financial Transaction

While most of CMS’s proposed changes are provider-friendly and designed to reduce regulatory burdens, CMS’s proposed change to the isolated financial transaction exception effectively decreases flexibility because parties can no longer use it to protect certain arrangements.  The isolated financial transaction exception allows for isolated transactions between physicians and entities even if the arrangement is not in writing as long as the arrangement meets certain requirements (e.g., the transaction must involve only a single payment within a six-month period).  Because the isolated financial transaction exception does not require a writing, it is less onerous than other similar exceptions, and thus has long been relied upon to protect various unwritten arrangements.  In particular, health care providers often rely on the isolated financial transaction exception where they discover that the parties have failed to document a services arrangement with a physician in writing, but the physician has already provided the services.   The parties cannot protect the arrangement under the exception for personal services or for fair market value compensation because the parties did not have a written arrangement that set the compensation in advance of the services being provided.  To remedy the situation, providers would pay for multiple services in a single payment during a six-month period, which is seemingly allowable under the isolated financial transaction exception.

CMS now makes clear that it does not sanction this common practice of relying on the isolated financial transaction exception to retroactively cure Stark Law noncompliance.  CMS thus proposes to amend the definition of “isolated financial transaction” to expressly exclude payment for multiple services provided over an extended period of time, even if there is only one payment for the services.  Although CMS deems this new definition to be a clarification of its long-standing policy, it is a fairly significant change from how this exception is commonly used in the industry.  We expect comments arguing that the plain language of the exception allows for a single payment for multiple services and that this new definition would increase the regulatory burden of the Stark Law.  

New Exception for Limited Remuneration to a Physician

Although the proposed new definition for “Isolated Financial Transaction” is not necessarily a welcome change because it restricts the ability to use the exception for certain arrangements, CMS is offering as consolation a new exception for limited remuneration provided to a physician without a written agreement or compensation that is set in advance (Limited Remuneration Exception).  This new exception is somewhat narrow because it only allows for payments that do not exceed $3,500 in the aggregate per calendar year, to be adjusted for inflation.  Although the exception does not require a written agreement, it otherwise includes several requirements commonly found in numerous other Stark Law exceptions (e.g., the remuneration must be FMV and cannot take into the volume or value of referrals, and the arrangement must be commercially reasonable).  The arrangement also must be for items or services actually provided by the physician. 

This exception would likely be used by parties who have historically relied upon the isolated financial transaction exception to make a single payment for multiple services without a written agreement, as discussed above.  CMS provides an example in which a hospital’s medical director resigns unexpectedly, and the hospital quickly arranges for a new medical director who starts performing services before a written agreement is drafted or the compensation is set.  If the aggregate compensation provided to the new medical director does not exceed the $3,500 annual limit, the parties could rely upon the Limited Remuneration Exception if all other conditions are met.  

The Limited Remuneration Exception could also be used in conjunction with other exceptions to protect an arrangement during the course of a calendar year in certain circumstances.  Using the medical director example above, the hospital could rely upon the Limited Remuneration Exception to protect initial payments to the physician up to the $3,500 annual limit and subsequently rely upon either the personal services arrangement exception or the fair market exception once the compensation is set and the arrangement is documented.

Similarly, entities could have separate arrangements with the same physician that meet a Stark Law exception (e.g. personal services arrangements or FMV exceptions), in which case the compensation for these separate arrangements would not be counted towards the annual limit.  However, if the entity has multiple undocumented compensation arrangements with a physician that otherwise do not meet an exception, this would be viewed as a single arrangement for which the aggregate compensation could not exceed $3,500 annual limit.

Note that the personal services arrangements exception requires that the arrangement cover all services to be provided by the physician, either by reference or cross-reference to a master list of contracts.  But CMS is not requiring that arrangements under the Limited Remuneration Exception be included, meaning that the services would not need to referenced in other physician contracts or listed in a master list of contracts.

While the health care industry is unlikely to turn down CMS’ offer of a new exception, we expect that many commenters will argue that the $3,500 amount is too low.  CMS is unlikely to listen unless commenters can offer supporting evidence for their position.    

Ownership or Investment Interests

The definition of “ownership or investment interest” includes a carve-out provision for certain interests, including those arising from a retirement plan, certain stock options and securities, and certain unsecured loans.  CMS is seeking to add to that carve-out a “titular ownership or investment interest,” which would be defined as an interest that excludes the ability or right to receive the financial benefits of ownership or investment, including the distribution of profits, dividends, proceeds of sale, or similar returns on investment.  CMS reasons that a physician with a titular ownership interest does not receive a distribution of profits or the proceeds of sale and thus would not have a financial incentive to make referrals to the entity in which the physician has a titular ownership or investment interest.  This change would align with CMS’s position, first introduced in the FY 2009 IPPS Final Rule, that titular ownership interests in physician organizations do not require physicians to stand in the shoes of the physician organization for the purposes of determining whether there is a direct compensation arrangement between the physicians and the physician organization.

In addition, CMS proposes to add to the carve-out an interest in an entity that arises through participation in an employee stock ownership plan (ESOP), which CMS believes merits the same protection that currently exists for interests arises from a retirement plan.  This proposal is a departure from its previous stance discussed in the FY 2009 IPPS final rule, which restricted the retirement interest carve-out to an interest in the entity arising from a retirement plan through the physician’s employment in that same entity.  Previously, if the retirement plan invested in a separate entity, that interest would not be carved out from the definition of “ownership or investment interest,” and the interest would need to satisfy a Stark Law exception in order for the physician to refer to the separate entity. 

However, CMS now recognizes that it is common in the industry to offer physician employees participation in an ESOP, and that such participation may result in the physician having an indirect ownership interest in a DHS entity that does not satisfy a Stark Law exception.  For legal and tax reasons, ESOPs are generally structured using a holding company.  In these situations, physician employees would be offered an interest in the holding company, and that holding company would own the DHS entity.  The result is a retirement plan that does not qualify for the retirement interest carve-out and, in fact, results in the physician having an indirect ownership interest in the DHS entity that may not satisfy a Stark exception.  Recognizing that ESOPs must comply with a number of safeguards under the Employee Retirement Income Security Act of 1974 (ERISA), particularly that employees cannot receive the value of their interests until at least one year after separation form their employee, CMS believes that ESOPs are nonabusive retirement plans that should be excluded from the definition of “ownership or investment interests.”

Stay tuned for more installments of this blog series covering additional proposed changes to numerous Stark Law exceptions, and a new AKS safe harbor for patient support tools and modifications to existing safe harbors related to beneficiary inducement.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Mintz - Health Care Viewpoints | Attorney Advertising

Written by:

Mintz - Health Care Viewpoints
Contact
more
less

Mintz - Health Care Viewpoints on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.